Valuation: Outlook Therapeutics, Inc.

Market Cap 20Cr 18Cr 17Cr 15Cr 29Cr 1.96TCr 30Cr 198.84Cr 77Cr 957.1Cr 77Cr 75Cr 3.32TCr P/E 2026 *
-3.45x
P/E 2027 * -5.63x
Enterprise Value 20Cr 18Cr 17Cr 15Cr 29Cr 1.96TCr 30Cr 198.84Cr 77Cr 957.1Cr 77Cr 75Cr 3.32TCr EV / Sales 2026 *
170x
EV / Sales 2027 * 4.47x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+6.51%
1 week+22.07%
Current month+11.32%
1 month+151.17%
3 months+696.58%
6 months+200.00%
Current year+12.03%
1 week 1.3
Extreme 1.3
1.87
1 month 0.7
Extreme 0.697
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
02/06Buy

Director

29,000 0.0181%
28/05
Gms Ventures & Investments
BuyCompany 3,95,16,849 24.6751%
27/05Buy

Chairman

1,22,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+6.51%+22.07%-9.23%-94.88% 20Cr
+1.50%+3.08%+3.45%+10.10% 4.94TCr
+1.89%+2.03%+401.26%+609.61% 4.03TCr
+2.93%+0.60%+28.55%-5.08% 3.4TCr
+1.22%+2.42%+19.22%+58.34% 3.36TCr
-0.79%+1.32%+5.78%+36.42% 2.68TCr
+1.21%+2.64% - - 1.72TCr
+1.28%-3.92%+66.92%+121.57% 1.52TCr
-19.44%-17.06%+58.41%+62.39% 1.4TCr
+2.62%-0.49%+15.24%+20.83% 1.34TCr
Average -0.18%+2.82%+65.51%+91.03% 2.44TCr
Weighted average by Cap. +0.22%+1.55%+88.87%+135.89%

Financials

2026 *2027 *
Net sales 12L 10.53L 10L 9L 17.02L 11Cr 17.36L 1.17Cr 45.39L 5.62Cr 45.06L 44.08L 20Cr 4.57Cr 4.01Cr 3.7Cr 3.42Cr 6.49Cr 437.85Cr 6.62Cr 45Cr 17Cr 214.27Cr 17Cr 17Cr 743.81Cr
Net income -5.22Cr -4.58Cr -4.23Cr -3.9Cr -7.4Cr -499.63Cr -7.55Cr -51Cr -20Cr -244.5Cr -20Cr -19Cr -848.77Cr -4.23Cr -3.71Cr -3.43Cr -3.17Cr -6Cr -405.32Cr -6.12Cr -41Cr -16Cr -198.35Cr -16Cr -16Cr -688.55Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
09/26/09 $1.794 +6.15% 45,48,177
08/26/08 $1.690 +15.75% 1,25,42,793
07/26/07 $1.460 +2.82% 47,61,647
06/26/06 $1.420 -2.07% 73,53,091
02/26/02 $1.450 -1.36% 51,65,541
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.690USD
Average target price
5.500USD
Spread / Average Target
+225.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock